<DOC>
	<DOC>NCT01982396</DOC>
	<brief_summary>Cross-over 28 week study of the plasma pharmacokinetic profiles of twice daily 3TC (4mg/kg/dose BD) with once daily 3TC (8mg/kg/dose OD) and twice daily ABC (8mg/kg/dose BD) with daily ABC (16mg/kg/dose OD) where one or both drugs are being taken as part of combination antiretroviral therapy.</brief_summary>
	<brief_title>Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Children with definitive HIV infection Age &gt; 2 and &lt; 13 years Currently on combination ART including 3TC and / or ABC, for at least 6 months, with stable CD4 cell count and HIV RNA viral load and expected to stay on this regimen for at least a further 3 months. â€¢ Intercurrent illness Receiving concomitant therapy except prophylaxis against Pneumocystis carinii pneumonia (PCP) Abnormal renal or liver function (grade 3 or above)</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>paediatric</keyword>
	<keyword>Abacavir</keyword>
	<keyword>lamivudine</keyword>
</DOC>